Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 903714 | ISIN: FR0000032658 | Ticker-Symbol: YSY
Frankfurt
17.01.25
08:01 Uhr
29,500 Euro
0,000
0,00 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
SYNERGIE SE Chart 1 Jahr
5-Tage-Chart
SYNERGIE SE 5-Tage-Chart
RealtimeGeldBriefZeit
29,20030,40018.01.
GlobeNewswire (Europe)
127 Leser
Artikel bewerten:
(0)

In challenging market conditions, SYNERGIE continues to grow while preserving its financial robustness

Finanznachrichten News

PRESS RELEASE | September 25th 2024, 5.45pm

IN CHALLENGING MARKET CONDITIONS, SYNERGIE CONTINUES TO GROW WHILE PRESERVING ITS FINANCIAL ROBUSTNESS

Revenue: €1,555.4 million
EBITDA: €63.3 million
Net profit: €31.7 million

On September 25th, 2024, the SYNERGIE Board of Directors, chaired by Mr Victorien Vaney,
approved the consolidated half-year financial statements for the period ended 30 June 2024. The auditing procedures for these financial statements are complete and the corresponding reports are being issued.

Consolidated - in € million H1 2024 H1 2023 Change %
Revenue 1,555.4 1,511.0 +2.9%
EBITDA 63.3 75.8 -16.5%
EBITA* 50.4 63.7 -20.8%
Operating profit 46.2 61.4 -24.6%
Net profit 31.7 41.2 -23.1%
Net profit Group share 29.4 38.9 -24.5%

* Recurring EBIT before amortisation and impairment of intangible assets

REVENUE OF €1,555.4 MILLION
SYNERGIE, a European leader in the Human Resources sector, generated revenues of €1,555.4 million, up +2.9% (+1.6% on a like-for-like basis), amid a market downturn in the Group's main countries. This performance was possible thanks to the contribution of all geographic areas where the Group operates. Synergie outperformed a declining market validating the Group's business strategy of a diversified portfolio of clients, sectors, and geographies.

In France, the first half of the year was marked by a decline in growth (-2.6%), driven by a decrease in staffing market volumes with a significant downturn in the last two months due to the climate of political and economic uncertainty.
International reached 59% of total revenues (versus 57% in 2023), with Southern Europe achieving revenues of €531.8 million. International growth of +7.1% was driven by organic growth (excluding exchange rates impact) of +4.8% and the impact of the acquisition of the RUNTIME Group in Germany (completed in May 2023), which generated €16 million during the period. The performance of Northern and Eastern Europe (+9.8%) remained strong despite the economic slowdown also felt in these countries.

EBITDA AND CURRENT OPERATING PROFIT (EBITA)

In the first half of 2024, SYNERGIE achieved an EBITDA of €63.3 million (4.1% of revenue), versus €75.8 million in H1 2023. This decline in EBITDA is attributed to the economic slowdown, the effects of regulatory changes in some countries and the Group's continued investment efforts to support its growth and digitalization.

The Current Operating Profit (EBITA) reached €50.4 million (3.2% of revenue) with a €22.1 million (43.9% of Current Operating Profit) contribution from International business, while France contributed €28.3 million (56.1% of Current Operating Profit).

OPERATING PROFIT

Operating profit came to €46.2 million, in line with the trend of Current Operating Profit.

NET PROFIT

After Tax expenses of €18.7 million and a Financial Result of €4.1 million, the consolidated Net Profit amounted to €31.7 million (of which the Group's share is €29.4 million).

A STRENGTHENED FINANCIAL STRUCTURE

With shareholders' equity of €690.3 million as of June 30 and cash position net of debt of €313.0 million, the Group reinforces its financial strength.

OUTLOOK FOR H2

Despite the economic challenges faced in certain markets during the first half of 2024, with the contraction of the staffing market in France and other European countries, SYNERGIE remains confident, thanks to its continued diversification and international expansion strategy, in its ability to achieve higher revenues in the second half of the year, but in this context remains very cautious about its capacity to improve operational profitability.

SYNERGIE financial structure remains strong, and the company intends to pursue new acquisitions, both in France and abroad.

NEXT EVENT

Communication of Revenues for the 3rd quarter of 2024 on Wednesday October 23rd, 2024,

after the stock market closing.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.